These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Scheinfeld N J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167 [TBL] [Abstract][Full Text] [Related]
7. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. Mercier RC; Stumpo C; Rybak MJ J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002 [TBL] [Abstract][Full Text] [Related]
8. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Poulakou G; Giamarellou H Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056 [TBL] [Abstract][Full Text] [Related]
9. Oritavancin: a new avenue for resistant Gram-positive bacteria. Mercier RC; Hrebickova L Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849 [TBL] [Abstract][Full Text] [Related]
10. Oritavancin for acute bacterial skin and skin structure infections. Messina JA; Fowler VG; Corey GR Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197 [TBL] [Abstract][Full Text] [Related]
11. Investigational new drugs for the treatment of resistant pneumococcal infections. Hoffman-Roberts HL; C Babcock E; Mitropoulos IF Expert Opin Investig Drugs; 2005 Aug; 14(8):973-95. PubMed ID: 16050791 [TBL] [Abstract][Full Text] [Related]
12. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Guay DR Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788 [TBL] [Abstract][Full Text] [Related]
13. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Crandon J; Nicolau DP Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390 [TBL] [Abstract][Full Text] [Related]
14. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Klinker KP; Borgert SJ Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277 [TBL] [Abstract][Full Text] [Related]
16. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Roberts KD; Sulaiman RM; Rybak MJ Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480 [TBL] [Abstract][Full Text] [Related]